LRH-1 governs vital transcriptional programs in endocrine-sensitive and -resistant breast cancer cells

Cancer Research

Volumn 74, Issue 7, 2014, Pages 2015-2025

  Bianco, Stéphanie ^a   Brunelle, Myléne ^a   Jangal, Maïka ^a   Magnani, Luca ^b   Gévry, Nicolas ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CCND1 PROTEIN; LIVER RECEPTOR HOMOLOG 1; RNA POLYMERASE II; TRANSCRIPTOME; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CCND1 GENE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER RECEPTOR HOMOLOG 1 GENE; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

BINDING SITES; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMATIN; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; HUMANS; MCF-7 CELLS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; TRANSCRIPTION, GENETIC;

EID: 84897444768     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2351     Document Type: Article

References (54)

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Early breast cancer trialists' collaborative group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-Analysis of randomised trials. Lancet 2011;378:771-84.
2. Sweeney EE, McDaniel RE, Maximov PY, Fan P, Jordan VC. Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Horm Mol Biol Clin Investig 2012;9:143-63.
3. Bianco S, Gevry N. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription 2012;3: 165 -70.
4. Svotelis A, Bianco S, Madore J, Huppe G, Nordell-Markovits A, Mes-Masson AM, et al. H3K27 demethylation by JMJD3 at a poised enhancer of anti-Apoptotic gene BCL2 determines ERalpha ligand dependency. Embo J 2011;30:3947-61.
5. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011;43:27-33.
6. Magnani L, Ballantyne EB, Zhang X, Lupien M. PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet 2011;7:e1002368.
7. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012;481: 389-93.
8. Burris TP, Busby SA, Griffin PR. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 2012;19:51-9.
9. Musille PM, Pathak MC, Lauer JL, Hudson WH, Griffin PR, Ortlund EA. Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation. Nat Struct Mol Biol 2012;19:532-7.
10. Whitby RJ, Stec J, Blind RD, Dixon S, Leesnitzer LM, Orband-Miller LA, et al. Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2). J Med Chem 2011;54:2266-81.
11. Busby S, Nuhant P, Cameron M, Mercer BA, Hodder P, Roush WR, et al. Discovery of inverse agonists for the liver receptor homologue-1 (LRH1; NR5A2). Probe Reports from the NIH Molecular Libraries Program[Internet]. Bethesda (MD): National Center for Biotechnology Information (US). 2010 [updated 2011 Dec 12].
12. Rey J, Hu H, Kyle F, Lai CF, Buluwela L, Coombes RC, et al. Discovery of a new class of liver receptor homolog-1 (LRH-1) antagonists: virtual screening, synthesis, and biological evaluation. ChemMedChem 2012.
13. Lazarus KA, Wijayakumara D, Chand AL, Simpson ER, Clyne CD. Therapeutic potential of liver receptor homolog-1 modulators. J Steroid Biochem Mol Biol 2012;130:138-46.
14. Duggavathi R, Volle DH, Mataki C, Antal MC, Messaddeq N, Auwerx J, et al. Liver receptor homolog 1 is essential for ovulation. Genes Dev 2008;22:1871-6.
15. Zhang C, Large MJ, Duggavathi R, Demayo FJ, Lydon JP, Schoonjans K, et al. Liver receptor homolog-1 is essential for pregnancy. Nat Med 2013.
16. Botrugno OA, Fayard E, Annicotte JS, Haby C, Brennan T, Wendling O, et al. Synergy between LRH-1 and beta-catenin induces G1 cyclinmediated cell proliferation. Mol Cell 2004;15:499-509.
17. Benod C, Vinogradova MV, Jouravel N, Kim GE, Fletterick RJ, Sablin EP. Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation. Proc Natl Acad Sci U S A 2011;108:16927-31.
18. Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, et al. The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene 2005;24:8167-75.
19. Miki Y, Clyne CD, Suzuki T, Moriya T, Shibuya R, Nakamura Y, et al. Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of in situ steroidogenesis. Cancer Lett 2006;244:24-33.
20. Chand AL, Herridge KA, Thompson EW, Clyne CD. The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion. Endocr Relat Cancer 2010;17:965-75.
21. Svotelis A, Gevry N, Gaudreau L. Chromatin immunoprecipitation in mammalian cells. Methods Mol Biol 2009;543:243-51.
22. Li H, Durbin R. Fast and accurate short read alignment with burrowswheeler transform. Bioinformatics 2009;25:1754-60.
23. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008; 9:R137.
24. Shin H, Liu T, Manrai AK, Liu XS. CEAS: cis-regulatory element annotation system. Bioinformatics 2009;25:2605-6.
25. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010;28:495-501.
26. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cisregulatory elements required for macrophage and B cell identities. Mol Cell 2010;38:576-89.
27. Ye T, Krebs AR, Choukrallah MA, Keime C, Plewniak F, Davidson I, et al. seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res 2011;39:e35.
28. Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P, et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 2012;148:84-98.
29. Boyle AP, Guinney J, Crawford GE, Furey TS. F-Seq: a feature density estimator for high-Throughput sequence tags. Bioinformatics 2008; 24:2537-8.
30. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14:178-92.
31. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997;57:3486-93.
32. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993;53:3229-32.
33. Heng JC, Feng B, Han J, Jiang J, Kraus P, Ng JH, et al. The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell 2010;6:167-74.
34. Simon JM, Giresi PG, Davis IJ, Lieb JD. Using formaldehyde-Assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA. Nat Protoc 2012;7:256-67.
35. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 2010;107:21931-6.
36. Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature 2010;467:430-5.
37. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011;474:390-4.
38. De Santa F, Barozzi I, Mietton F, Ghisletti S, Polletti S, Tusi BK, et al. A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol 2010;8:e1000384.
39. Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, et al. Widespread transcription at neuronal activity-regulated enhancers. Nature 2010;465:182-7.
40. Holmstrom SR, Deering T, Swift GH, Poelwijk FJ, Mangelsdorf DJ, Kliewer SA, et al. LRH-1 and PTF1-L coregulate an exocrine pancreasspecific transcriptional network for digestive function. Genes Dev 2011;25:1674-9.
41. Tang Q, Chen Y, Meyer C, Geistlinger T, Lupien M, Wang Q, et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res 2011;71:6940-7.
42. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA,Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011;470:279-83.
43. Zentner GE, Tesar PJ, Scacheri PC. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res 2011;21:1273-83.
44. Chong HK, Biesinger J, Seo YK, Xie X, Osborne TF. Genome-wide analysis of hepatic LRH-1 reveals a promoter binding preference and suggests a role in regulating genes of lipid metabolism in concert with FXR. BMC Genomics 2012;13:51.
45. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, et al. An oestrogen-receptor-Alpha-bound human chromatin interactome. Nature 2009;462:58-64.
46. Hah N, Murakami S, Nagari A, Danko C, Kraus WL. Enhancer transcripts mark active estrogen receptor binding sites. Genome Res 2013.
47. Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W, et al. The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat 2011; 127:385-96.
48. Chand AL, Wijayakumara DD, Knower KC, Herridge KA, Howard TL, Lazarus KA, et al. The orphan nuclear receptor LRH-1 and ERalpha activate GREB1 expression to induce breast cancer cell proliferation. PLoS ONE 2012;7:e31593.
49. Lazarus KA, Zhao Z, Knower KC, To SQ, Chand AL, Clyne CD. Oestradiol reduces liver receptor homolog-1 mRNA transcript stability in breast cancer cell lines. Biochem Biophys Res Commun 2013;438:533-9.
50. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, et al. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 2009;69:5415-23.
51. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 2011;128:457-66.
52. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010;204:105-14.
53. Wang D, Hu L, Zhang G, Zhang L, Chen C. G protein-coupled receptor 30 in tumor development. Endocrine 2010;38:29-37.
54. Chand AL, Herridge KA, Howard TL, Simpson ER, Clyne CD. Tissuespecific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts. Steroids 2011; 76:741-4.